Asian Spectator

Eisai to Present Latest Data on Alzheimer's Disease / Dementia Pipeline at 12th Clinical Trials on Alzheimer's Disease Conference

  • Written by ACN Newswire - Press Releases

Eisai to Present Latest Data on Alzheimer's Disease / Dementia Pipeline at 12th Clinical Trials on Alzheimer's Disease Conference

TOKYO, Dec 2, 2019 - (JCN Newswire) - Eisai Co., Ltd. announced today that three oral presentations and eight poster presentations, highlighting the latest data on its Alzheimer's disease / dementia pipeline including anti-amyloid beta (Abeta) protofibril antibody BAN2401, orexin receptor antagonist lemborexant and a simple blood diagnostic for Alzheimer's disease (AD), will be given at the 12th Clinical Trials on Alzheimer's Disease (CTAD) conference taking place in San Diego, California in the United States, from December 4 to 7, 2019. BAN2401 is being jointly developed by Eisai and Biogen Inc. In addition, the simple blood diagnostics for AD are being jointly developing by Eisai and Sysmex Corporation.

For BAN2401, the persistance of brain Abeta levels in patients with early AD at the beginning of the open label extension phase of the Phase II study (Study 201) will be presented in Late-Breaking Oral Communications Session. Study 201 is a first late-stage study which successfully demonstrated the potential disease-modifying effects on both clinical function and Abeta accumulation in the brain. In addition, the study design and current status of ongoing Clarity AD (Study 301) will be presented.

Meanwhile, for the investigational sleep-wake regulation agent lemborexant, the further data analysis results from Phase II clinical study (Study 202) for AD patients with irregular sleep-wake rhythm disorder (ISWRD) will be given.

In addition, regarding the creation of the simplified blood diagnostics for AD, jointly developed with Sysmex, the latest data of the fully automated protein assay system using the Sysmex's automated protein measurement immunoassay platform HISCLTM series will be presented.Eisai is aiming to realize prevention and cure of dementia through a holistic approach to dementia drug discovery research based on a foundation of over 35 years of experience of drug discovery activities in the area of Alzheimer's disease / dementia. Eisai is striving to create innovative medicines as soon as possible in order to further contribute to addressing the unmet medical needs of, as well as increasing the benefits provided to, patients and their families.

About BAN2401

BAN2401 is a humanized monoclonal antibody for Alzheimer's disease (AD) that is the result of a strategic research alliance between Eisai and BioArctic. BAN2401 selectively binds to neutralize and eliminate soluble, toxic Abeta aggregates (protofibril) that are thought to contribute to the neurodegenerative process in AD. As such, BAN2401 may have the potential to have an effect on disease pathology and to slow down the progression of the disease. Eisai obtained the global rights to study, develop, manufacture and market BAN2401 for the treatment of AD pursuant to an agreement concluded with BioArctic in December 2007. Currently, a global clinical phase III study (Clarity AD) of BAN2401 in early AD is underway.

About the Joint Development Agreement between Eisai and Biogen for AD

Eisai and Biogen are widely collaborating on the joint development and commercialization of AD treatments. Eisai serves as the lead in the co-development of BAN2401, an anti-Abeta protofibril antibody, while Biogen serves as the lead for co-development of aducanumab, Biogen's investigational anti-Abeta antibody for patients with AD, and the companies plan to pursue marketing authorizations for the two compounds worldwide. If approved, the companies will also co-promote the products in major markets, such as the United States, the European Union and Japan.

About Lemborexant

Lemborexant, an orexin receptor antagonist, is Eisai's in-house discovered and developed small molecule that inhibits orexin neurotransmission by binding competitively to the two subtypes of orexin receptors (orexin receptor 1 and 2). Faster on/off receptor kinetics of lemborexant to orexin receptor 2, which also suppresses non-REM sleep, indicate its potential to be facilitate the onset and maintenance of sleep. As a result of clinical studies, the effect of lemborexant are suggested not only for primary insomnia but also for insomnia which the diseases, such as depression, associated with. Eisai has submitted new drug applications seeking approval of lemborexant for use in the treatment of insomnia disorder in the United States (December 2018), Japan (March 2019), and Canada (August 2019), respectively. Additionally, a Phase II clinical study of lemborexant in patients with ISWRD associated with mild to moderate Alzheimer's dementia is underway.

About collaboration between Eisai and Sysmex

Eisai and Sysmex have entered into a comprehensive non-exclusive collaboration agreement aimed at the creation of new diagnostics in the field of dementia in February, 2016. Leveraging each other's technologies and knowledge, the two companies aim to discover next-generation diagnostics that will enable early diagnosis, selection of treatment options and the regular monitoring of the effects of treatment for dementia.

HISCLTM is a trademark of Sysmex Corporation.

About Eisai

Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Neurology and Oncology.

In its medium-term business plan EWAY2025, Eisai is aiming to become a "Medico Societal Innovator" (a company that changes society through creating medicines and providing solutions), and is working on establishment of ecosystem platform business utilizing various data such as a large amount of clinical data, experiences, and know-how.

For more information about Eisai Co., Ltd., please visit https://www.eisai.co.jp.

Contact:Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120

Copyright 2019 JCN Newswire. All rights reserved. www.jcnnewswire.com

Authors: ACN Newswire - Press Releases

Read more //?#

Gallery on Cups: Nayuki Cupseum Releases New Design in Collabo...

SHENZHEN, China, May 29, 2020 /PRNewswire-AsiaNet/ -- Nayuki Cupseum is back for the third season on May 20, bringing a new series of cups featuring "Big Hugs" designed by Christopher David ...

DENSO Announces Changes in the Areas of Responsibility of Senior Executive Officers and Executive Officers

KARIYA, JAPAN, May 29, 2020 - (JCN Newswire) - DENSO Corporation today announced the addition of four new key positions in the CxO system as of June 1st and personal changes as follows. The...

Eisai: Results from LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Trials

TOKYO, May 29, 2020 - (JCN Newswire) - Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. known as MSD outside the United States and Canada, today announced that results from two tri...

100 Years of Maintaining the Status quo is Being Challenged by...

NEUCHATEL, Switzerland, May 29, 2020 /PRNewswire-AsiaNet/ -- Most of the cosmetics products and staple names known today were born out of the early Hollywood film industry in the 1920s with ...

Mundane Glory: Telling the Story of Chinese Overseas Medical Aid

CHANGSHA, China, May 29, 2020 /Xinhua-AsiaNet/-- Aired in Mango TV, Mundane Glory is a series of short documentary that focuses on strivers who work on Chinese emerging industry. It has been...

Optimization of Business Environment Stimulates the Recovery o...

CHANGSHA, China, May 29, 2020 /Xinhua-AsiaNet/-- Changsha, the capital city of Central China's Hunan province, issued multiple policies on optimization of business environment to stimulate a...

A Virtual Journey to Japan's Historical Treasures

TOKYO, May 29, 2020 /PRNewswire-AsiaNet/-- Travel through the rich cultural history of Japan, through castles, temples and shrines, magnificent natural beauty, and centuries-old traditional ...

va-Q-tec supports pharmaceutical industry in Asia with worldwide logistics of COVID-19 diagnostic kits

Made in Germany, va-Q-tech's high-tech thermal containers and boxes are vital for the international logistics of temperature-sensitive COVID19 diagnostic kits, drugs and vaccines.Lead...

Science and Technology Daily: China's Commitment in Global Fig...

BEIJING, May 29, 2020 /PRNewswire-AsiaNet/ -- A news report by Science and Technology Daily:The 73rd World Health Assembly (WHA) was held in a special period of time when the outbreak of COV...

Fukushima Pref. Creates PR Video Showing Status of Recovery fr...

FUKUSHIMA, Japan, May 29, 2020 /Kyodo JBN-AsiaNet/-- - English, Chinese (Simplified/Traditional Characters), Korean Versions Opened on Fukushima's Official YouTube Channel -The Fukushima Pre...

Coocaa S6G TV breaks e-commerce live streaming record on Lazada Vietnam with 1000 in sales

Lazada live streaming (LazLive) witnessed new record-high numbers in Vietnam on May 28, drew nearly 5000 views and more than 30.000 likes.  HO CHI MINH CITY, VIENAM - Media ...

Paice, Abell, and Daimler Agree to License Patented Technology

BALTIMORE, MD / ACCESSWIRE, May 29, 2020 - (ACN Newswire) - Paice and Daimler have reached an agreement to license patented hybrid technology.Paice was an early leader in electrified vehicl...

World No Tobacco Day, 31st May: Allen Carr's Easyway Celebrat...

LONDON, May 29, 2020 /PRNewswire-AsiaNet/ -- Coinciding with World No Tobacco Day on 31st May 2020, the international publishing agents for Allen Carr's Easyway, have revealed that this drug...

Huawei Announces the Next-Gen OceanStor Pacific Series, Settin...

SHENZHEN, China, May 29, 2020 /PRNewswire-AsiaNet/ -- Huawei announced the worldwide launch of the next-generation mass storage system -- OceanStor Pacific Series. The series delivers effici...

Risen Energy Has Been Included in the "Top Ten Module Brands i...

NINGBO, China, May 29, 2020 /PRNewswire-AsiaNet/-- The Fifth Century Photovoltaic Conference, co-organized by Century New Energy Network and Photovoltaic Brand Lab (PVBL), was recently held ...

AbbVie and Eisai Announce an Approval for Partial Changes in the Marketing Approval of HUMIRA, a Fully Human Anti-TNFalpha Monoclonal Antibody

TOKYO, May 29, 2020 - (JCN Newswire) - AbbVie GK and Eisai Co., Ltd. today announced an approval of partial changes in the marketing approval of HUMIRA (generic name: adalimumab [recombinan...

Favored Tech Announces Global Availability of FT-Nano Green 10...

CUPERTINO, Calif., May 29, 2020 /PRNewswire-AsiaNet/-- Favored Tech's early access customers have started production shipments of products protected by FT-Nano Green 1008, the most advanced ...

Food and beverage (F B) businesses to speed their digital transformation with digital marketing programme subsidised by Enterprise Singapore

Programme run by PSB Academy and subsidised by Enterprise Singapore, small and medium (SME) F&B businesses can now arm their staff with a suite of skills in promoting on essential platfo...

Asia Cloud Computing Association: Covid-19 Economic Resilience and Recovery Capability Reflected in the Cloud Readiness Index 2020

SINGAPORE - Media OutReach - 29 May 2020 - In the sixth iteration of the Asia Cloud Computing Association's Cloud Readiness Index, Hong Kong, Singapore, New Zealand, Taiwan, and Sout...



News Company Media Core

Content & Technology Connecting Global Audiences

More Information - Less Opinion